Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Post-BCMA Treatment Selection in R/R Multiple Myeloma
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Project Oncology®
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Steve Jackson, PharmD; Nisha Joseph, MD
- Steve Jackson, PharmD
- Nisha Joseph, MD
NEW EPISODE
Targeting PTEN: Why It Matters
Targeting PTEN: Why It Matters
MinuteCE®
Targeting PTEN: Why It Matters
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
ADT Intensification: The Evidence You Can’t Afford to Miss
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®
ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
De Novo mHSPC: Recognizing the Patients Who Need More
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®
De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Oncology and Hematology
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
- Chan Y. Cheah, MBBS
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Oncology and Hematology
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Nicolas Girard, MD; Louise Lim, MD
- Nicolas Girard, MD
- Louise Lim, MD
- Jacob Sands, MD
- Stephanie McDonald, MSN, FNP-BC, AOCNP
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits

Medical News

$talquetamab and daratumumab in relapsed or refractory myeloma$ $talquetamab and daratumumab in relapsed or refractory myeloma$
Medical News
Talquetamab and Daratumumab in Relapsed or Refractory Myeloma
06/18/2026
Read more
Medical News
Olaparib Plus Radium-223 Improves rPFS in COMRADE
06/18/2026
Read more
Medical News
Text Messaging and FIT Completion in a Quality Improvement Trial
06/18/2026
Read more
Medical News
PORTEC-4a Trial Reports Molecular Profile Guided Adjuvant Treatment
06/17/2026
Read more

CME/CE

NEW EPISODE
Molecular Profiling in mHSPC: Informing Treatment Selection
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®
Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE Virtual Event
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
1.50 credits
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
MinuteCE®
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits

Clinical Practice

6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Project Oncology®
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Steve Jackson, PharmD; Lyudmila A. Bazhenova, MD
- Steve Jackson, PharmD
- Lyudmila A. Bazhenova, MD
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits
Assessing and Interpreting pCR in Perioperative NSCLC
Assessing and Interpreting pCR in Perioperative NSCLC
Project Oncology®
Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD; Alexander Spira, MD, PhD, FACP
- Steve Jackson, PharmD
- Alexander Spira, MD, PhD, FACP
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 3 episodes

Programs

DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- Tiffany Traina, MD, FASCO
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP; Rohit Thummalapalli, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD
Key Differences in Pulmonary and Extrapulmonary NEC Management
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS; Lowell B. Anthony, MD, FACP
- Alexandria May, PharmD, BCPS
- Lowell B. Anthony, MD, FACP